OTIC - オトノミ― (Otonomy Inc.)

OTICのニュース

   Otonomy's OTO-825 Gene Therapy Can Restore Meaningful Hearing Function, Animal Study Shows  2021/05/14 18:59:13 Benzinga
Otonomy Inc (NASDAQ: OTIC ) may have hit a snag with the development of its lead ear disorder candidate Otividex . Still, the company is trumpeting an early win for a gene therapy designed to treat congenital hearing loss. The drug candidate, dubbed OTO-825, reduced hearing loss and repaired structural damage in the inner ear in two mouse models of genetically driven hearing deficiency. Otonomy and its partner Applied Genetic … Full story available on Benzinga.com
   The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron  2021/05/12 12:57:17 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ: HOOK ) Novo Nordisk A/S (NYSE: NVO ) West Pharmaceutical Services, Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 11) 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT ) 4D pharma plc (NASDAQ: LBPS ) Acutus Medical, Inc. (NASDAQ: AFIB ) Adagene Inc. (NASDAQ: ADAG ) Adaptive Biotechnologies Corporation (NASDAQ: ADPT ) ADC Therapeutics SA (NYSE: ADCT ) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Akouos, Inc. (NASDAQ: AKUS ) (reacted to presentation of non-clinical data on gene therapy candidates at the American Society of Gene and Cell Therapy meeting) Akoya Biosciences, Inc. (NASDAQ: AKYA ) Aprea Therapeutics, Inc. (NASDAQ: APRE ) Aptinyx Inc. (NASDAQ: APTX ) Aquestive Therapeutics, Inc. (NASDAQ: AQST ) ARCA biopharma, Inc. (NASDAQ: ABIO ) Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT ) (reacted to its first-quarter results) Assembly Biosciences, Inc.
   The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings  2021/05/11 11:54:30 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV ) - Its Allergan subsidiary announced a deal to buy Soliton, Inc. (NASDAQ: SOLY ) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Novo Nordisk A/S (NYSE: NVO ) Quest Diagnostics Incorporated (NYSE: DGX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 10) 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT ) 4D pharma plc (NASDAQ: LBPS ) Accelerate Diagnostics, Inc. (NASDAQ: AXDX ) Acutus Medical, Inc. (NASDAQ: AFIB ) Adagene Inc. (NASDAQ: ADAG ) Adaptive Biotechnologies Corporation (NASDAQ: ADPT ) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Akoya Biosciences, Inc. (NASDAQ: AKYA ) Aquestive Therapeutics, Inc. (NASDAQ: AQST ) Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) Athersys, Inc. (NASDAQ: ATHX ) Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH ) (reacted to publication of positive results for a late-stage asset in lupus nephritis) Autolus Therapeutics plc (NASDAQ: AUTL ) AVROBIO, Inc.
   Otonomy stock loses half its value after disappointing trial results of vertigo treatment  2021/02/22 13:37:26 MarketWatch
Shares of Otonomy Inc. undefined plunged 50.1% to pace all premarket decliners, after the biopharmaceutical company said Phase 3 trial of its Ménière's…
   Otitis Drug Market Analysis by Sanofi, Bristol-Myers Squibb Company, Otonomy Inc., Torrent Pharmaceuticals Ltd  2020/11/11 18:29:20 OpenPR
Otitis Drug Market By Type (Acute Otitis Media, Otitis Media with Effusion and Chronic Otitis Media with Effusion), Treatment Type (Medication and Surgery), Mechanism of Action Types (Corticosteroid, Topoisomerase Enzymes Type II Inhibitor, Cephalosporin Antibiotic and Anti-Infective), Route of Administration (Oral,
   Otonomy stock loses half its value after disappointing trial results of vertigo treatment  2021/02/22 13:37:26 MarketWatch
Shares of Otonomy Inc. undefined plunged 50.1% to pace all premarket decliners, after the biopharmaceutical company said Phase 3 trial of its Ménière's…
   Otitis Drug Market Analysis by Sanofi, Bristol-Myers Squibb Company, Otonomy Inc., Torrent Pharmaceuticals Ltd  2020/11/11 18:29:20 OpenPR
Otitis Drug Market By Type (Acute Otitis Media, Otitis Media with Effusion and Chronic Otitis Media with Effusion), Treatment Type (Medication and Surgery), Mechanism of Action Types (Corticosteroid, Topoisomerase Enzymes Type II Inhibitor, Cephalosporin Antibiotic and Anti-Infective), Route of Administration (Oral,
   Global Meniere's Disease Drug Market to Register Substantial Global Expansion by 2027, Get Understanding of COVID 19 effect on Industry: Abbott, Otonomy Inc., WellSpring Pharmaceutical Corporation, Sound Pharmaceutical  2020/11/06 15:05:35 OpenPR
Global Meniere's Disease Drug Market research report has been produced with the systematic gathering of market information for industry. All this information is supplied in such a way that it properly gives explanation of various facts and figures to the
   Otonomy, Inc. (NASDAQ:OTIC) Given Consensus Recommendation of “Buy” by Brokerages  2020/10/24 14:07:00 The Olympia Report
Otonomy, Inc. (NASDAQ:OTIC) has earned a consensus rating of “Buy” from the six brokerages that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on […]
   Booming Growth of Vertigo Drugs Market to Witness a Pronounce Growth at CAGR during 2020-2027| Auris Medical , Otonomy , Sensorion , Sound Pharmaceuticals  2020/10/15 10:18:37 OpenPR
The global analysis of Vertigo Drugs Market and its upcoming prospects have recently added by HealthCare Intelligence Markets to its extensive repository. It has been employed through the primary and secondary research methodologies. This market is expected to become competitive
   Otonomy stock loses half its value after disappointing trial results of vertigo treatment  2021/02/22 13:37:26 MarketWatch
Shares of Otonomy Inc. undefined plunged 50.1% to pace all premarket decliners, after the biopharmaceutical company said Phase 3 trial of its Ménière's…
   Otitis Drug Market Analysis by Sanofi, Bristol-Myers Squibb Company, Otonomy Inc., Torrent Pharmaceuticals Ltd  2020/11/11 18:29:20 OpenPR
Otitis Drug Market By Type (Acute Otitis Media, Otitis Media with Effusion and Chronic Otitis Media with Effusion), Treatment Type (Medication and Surgery), Mechanism of Action Types (Corticosteroid, Topoisomerase Enzymes Type II Inhibitor, Cephalosporin Antibiotic and Anti-Infective), Route of Administration (Oral,
   Global Meniere's Disease Drug Market to Register Substantial Global Expansion by 2027, Get Understanding of COVID 19 effect on Industry: Abbott, Otonomy Inc., WellSpring Pharmaceutical Corporation, Sound Pharmaceutical  2020/11/06 15:05:35 OpenPR
Global Meniere's Disease Drug Market research report has been produced with the systematic gathering of market information for industry. All this information is supplied in such a way that it properly gives explanation of various facts and figures to the
   Otonomy, Inc. (NASDAQ:OTIC) Given Consensus Recommendation of “Buy” by Brokerages  2020/10/24 14:07:00 The Olympia Report
Otonomy, Inc. (NASDAQ:OTIC) has earned a consensus rating of “Buy” from the six brokerages that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on […]
   Booming Growth of Vertigo Drugs Market to Witness a Pronounce Growth at CAGR during 2020-2027| Auris Medical , Otonomy , Sensorion , Sound Pharmaceuticals  2020/10/15 10:18:37 OpenPR
The global analysis of Vertigo Drugs Market and its upcoming prospects have recently added by HealthCare Intelligence Markets to its extensive repository. It has been employed through the primary and secondary research methodologies. This market is expected to become competitive

calendar